MetaCap

Atea Pharmaceuticals (AVIR) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atea Pharmaceuticals (AVIR) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 33.3% versus a loss of 61.0%. Over five years, AVIR leads with a -51.4% price change compared with -58.8% for SPRY. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $297.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVIR+33.33%SPRY-61.00%
+116%+21%-74%
Nov 21, 20251 yearNov 20, 2026
AVIR-51.17%SPRY-63.99%
+131%+27%-76%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVIR versus SPRY key metrics
MetricAVIRSPRY
Share price$3.96$2.96
Market cap$318.00M$297.56M
1-day change+0.76%-11.90%
YTD return+10.92%-74.59%
1-year return+33.33%-61.00%
5-year return-51.35%-58.83%
EPS (TTM)$-1.95$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$84.28M
Revenue growth (YoY)—-5.46%
Net income (latest FY)$-158.35M$-171.30M
Operating margin—-212.92%
Net margin—-203.25%
52-week high$6.45$13.15
52-week low$2.96$2.44
Distance from 52-week high-38.60%-77.49%
Analyst consensusbuystrong_buy
Avg. price target upside+127.27%+474.32%
Average volume290.60K1.83M
Shares outstanding80.30M100.53M
Employees55203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AVIR has outperformed SPRY by 94.3 percentage points over the past year.

About Atea Pharmaceuticals

AVIR stock →

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

AVIR vs SPRY FAQ

Which is bigger, Atea Pharmaceuticals or ARS Pharmaceuticals?

Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $297.56M for ARS Pharmaceuticals (SPRY).

Which stock has performed better over the past year, AVIR or SPRY?

AVIR returned +33.33% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.

Are Atea Pharmaceuticals and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons